12/3/2008 12:37:46 PM
NORWOOD, Mass.--(BUSINESS WIRE)--AiRNA Pharmaceuticals, Inc., a RNAi therapeutics company based on next generation proprietary RNAi technologies, and Boston Biomedical, Inc., a biotechnology company developing novel therapies targeting cancer stem cells, today announced that asymmetrical interfering RNA (aiRNA), a new fundamental RNAi technology discovered by the companies, is being published in the December issue of Nature Biotechnology. The publication titled “Asymmetric RNA Duplexes Mediate RNA Interference in Mammalian Cells” highlights that the smaller 15 bp aiRNA can target a variety of genes with superior efficiency than the standard 19-21 bp siRNA. Furthermore, the new aiRNA structure can target genes more selectively with significantly less off-target effects than the standard 19-21 bp siRNA. These results establish aiRNA as a new and superior structure to silence genes.
comments powered by